Twist Bioscience, a San Francisco, CA-based developer of a DNA synthesis process, raised an additional $33m in funding.
The backers were not disclosed.
The company, which has raised a total of $166m, intends to use the funds to further accelerate growth of its core gene synthesis business, as well as pharmaceutical discovery and data storage vertical strategies.
Led by Emily M. Leproust, Ph.D., CEO, Twist Bioscience has developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high throughput silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries. By synthesizing DNA on silicon, the platform enables high-quality and high throughput synthetic gene production, which in turn, expedites the design, build and test cycle to enable personalized medicines, pharmaceuticals, sustainable chemical production, improved agriculture production, diagnostics and biodetection.